drugset / Trial / NCT00257426
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase 2
Completed
31 enrolled
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Octreotide may stop or slow the growth of tumor cells and may be an effective treatment for liver cancer. PURPOSE: This phase II trial is studying how well octreotide works in treating patients with locally advanced or metastatic liver cancer.
Timeline
- Start
- 2005-07
- Primary completion
- 2007-02
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octreotide | Peptide | 200 ug | Subcutaneous |